---
title: "Novartis’ pelacarsen fails Phase 3 HORIZON trial, missing heart-outcome benefit"
id: "news-news-stat-4120cb9a835227a43a9b1c43"
canonical_url: "https://medichelpline.com/news/news-news-stat-4120cb9a835227a43a9b1c43"
content_type: "medical_news_article"
category: "Biotech"
source_name: "STAT News"
source_url: "https://www.statnews.com/2026/09/04/novartis-therapy-pelacarsen-fails-cardiovascular-trial/?utm_campaign=rss"
published_at: "2026-09-04T21:07:27.000Z"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Novartis’ pelacarsen fails Phase 3 HORIZON trial, missing heart-outcome benefit
## Metadata & Source Attribution
- **Canonical URL:** https://medichelpline.com/news/news-news-stat-4120cb9a835227a43a9b1c43
- **Category:** [Biotech](https://medichelpline.com/news/biotech.md)
- **Reporting Source:** STAT News
- **Original Source URL:** [Read Original Article](https://www.statnews.com/2026/09/04/novartis-therapy-pelacarsen-fails-cardiovascular-trial/?utm_campaign=rss)
- **Published At:** 2026-09-04T21:07:27.000Z
## Executive Summary & Key Highlights
- Novartis said on Sept. 4, 2026 that its investigational drug **pelacarsen** did not lower the risk of cardiovascular death or emergency events such as heart attack or stroke in the Phase 3 **HORIZON** trial compared with placebo. - Earlier studies had shown pelacarsen could substantially reduce levels of **Lp(a)**, a lipid-protein particle linked to increased cardiovascular risk, but that biomarker reduction did not translate to improved clinical outcomes in this pivotal study. - The failure represents a setback for Novartis’ development program and for efforts to target **Lp(a)** as a strategy to prevent major cardiovascular events. - The article notes other companies, including **Amgen** and **Eli Lilly**, are also developing therapies aimed at lowering **Lp(a)**, underscoring broader industry interest despite this trial result. - The STAT report provides core trial outcome information but did not report additional details such as effect sizes, statistical results, enrollment numbers, or Novartis’ immediate next steps for the program.
## In-Depth Reporting & Editorial Analysis
## Novartis says pelacarsen did not improve major heart outcomes in Phase 3 trial Novartis reported on Sept. 4, 2026 that its experimental cardiovascular therapy **pelacarsen** failed to reduce the risk of cardiovascular death and emergency events such as heart attack or stroke in the Phase 3 **HORIZON** trial when compared with placebo. The result is a significant setback for the company’s program targeting elevated levels of **Lp(a)**, a lipid–protein particle associated with higher risk of serious cardiovascular disease. The company’s announcement followed earlier clinical work in which pelacarsen demonstrated the ability to markedly lower **Lp(a)** levels. Those biomarker reductions, however, did not translate into the hoped-for benefit on hard clinical endpoints in this pivotal study. ## What the trial outcome means for pelacarsen and Lp(a) research Drug developers and clinicians have been watching therapies that target **Lp(a)** closely because elevated levels of the particle are linked to an increased likelihood of major heart problems. Pelacarsen had been among the most closely followed candidates after early-stage studies showed strong reductions in **Lp(a)**. Novartis’ disclosure that the Phase 3 **HORIZON** trial did not demonstrate a reduction in cardiovascular death or emergency events means that lowering the biomarker alone did not prove sufficient, at least in this trial, to improve those clinical outcomes. The finding will likely prompt reappraisal across companies pursuing **Lp(a)**-lowering strategies and among researchers studying the relationship between the biomarker and cardiovascular events. ## Industry context: other companies pursuing Lp(a) approaches The STAT report notes that other large biopharma firms, including **Amgen** and **Eli Lilly**, are developing therapies designed to lower **Lp(a)**. The failure of pelacarsen in HORIZON does not eliminate interest in the pathway, but it does raise questions about whether alternative agents, dosing strategies, trial designs, patient selection, or longer follow-up will be required to show clinical benefit. ## What the published report did and did not include The STAT article provides the core outcome: pelacarsen did not reduce the risk of cardiovascular death or emergency cardiovascular events versus placebo in the Phase 3 HORIZON trial. It also reiterates that pelacarsen had reduced **Lp(a)** in earlier studies. The STAT piece did not report additional trial details in its public posting. Specifics such as the trial’s enrollment size, participant characteristics, length of follow-up, numerical effect sizes, statistical confidence measures, subgroup results, safety data, or Novartis’ immediate plans for the program were not included in the excerpt available from the source. ## Why the result matters for patients and the field Cardiovascular disease remains a leading cause of death globally, and finding new ways to reduce the risk of heart attacks, strokes, and cardiovascular death is a central goal of many development programs. **Lp(a)** has been considered a promising target because of its association with risk, and several companies invested in therapies aimed at lowering its levels. A negative pivotal trial such as HORIZON affects multiple stakeholders: it can influence clinical practice expectations, investor assessments of programs that target **Lp(a)**, regulatory considerations for related drugs, and the design of future studies investigating the pathway. It also highlights the distinction between changing a biomarker and demonstrating a meaningful reduction in clinical events. ## Next steps and unanswered questions The STAT piece did not describe Novartis’ next steps for the pelacarsen program, any planned analyses of the HORIZON data, or whether the company will pursue additional studies or regulatory dialogue. It also did not provide details on safety findings from the trial or whether any subgroups experienced benefit. Those details will be important for understanding whether the HORIZON outcome closes the book on pelacarsen and whether lessons from the trial will inform other **Lp(a)** programs. Observers will look for further communications from Novartis, full data releases, and peer-reviewed publication of the HORIZON results to learn more about the trial’s design, outcomes, and implications. Other companies working on **Lp(a)**-lowering therapies will likely interpret these results in the context of their own development plans, and regulators and clinicians will await more comprehensive data before drawing broader conclusions. ## Reporting details This coverage is based on a STAT News report by Andrew Joseph published Sept. 4, 2026. The STAT article provided the key outcome from Novartis’ announcement but did not include the fuller set of trial data or Novartis’ stated next steps in the public excerpt.
## Navigation
- [← Back to Biotech News](https://medichelpline.com/news/biotech.md)
- [← All Medical News Categories](https://medichelpline.com/news.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.